Last reviewed · How we verify
A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
The primary objective of this study is to determine the safe and tolerable dose level of OPB-111077 for patients with advanced cancer.
Details
| Lead sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 145 |
| Start date | 2012-06 |
| Completion | 2015-12 |
Conditions
- Solid Tumors
Interventions
- OPB-111077
Primary outcomes
- Safety and tolerability of OPB-111077 — 28 Days
AEs, Vital signs,Body weight, ECGs, Laboratory tests, Performance status
Countries
United States